NCT06516978 - A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL | Biotech Hunter

Enrollment

528

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

October 1, 2028

Study Completion Date

April 1, 2029

Conditions

Diffuse Large B Cell Lymphoma

Interventions

DRUG

Polatuzumab vedotin

Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.

DRUG

Rituximab

Rituximab IV infusion will be administered as per the schedule specified in the respective arm.

DRUG

Cyclophosphamide

Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.

DRUG

Doxorubicin

Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.

DRUG

Vincristine

Vincristine IV infusion will be administered as per the schedule specified in the respective arm.

DRUG

Prednisone

Prednisone PO will be administered as per the schedule specified in the respective arm.

DRUG

Orelabrutinib

Orelabrutinib PO will be administered as per the schedule specified in the respective arm.

DRUG

Venetoclax

Venetoclax PO will be administered as per the schedule specified in the respective arm.

DRUG

Chidamide

Chidamide PO will be administered as per the schedule specified in the respective arm.

DRUG

Penpulimab

Penpulimab IV infusion will be administered as per the schedule specified in the respective arm.

DRUG

Lenalidomide

Lenalidomide PO will be administered as per the schedule specified in the respective arm.

All Listed Sponsors

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER